Group Administrators Office
Canadian Cancer Trials Group Announces Activation of Canadian Cancer Trials Group BR.31:
A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 in Completely Resected Non-Small Cell Lung Cancer
The Canadian Cancer Trials Group (Canadian Cancer Trials Group) has developed and will lead an international clinical trial of a new class of cancer drug aimed at curing non-small cell lung cancer (NSCLC) in patients who have had surgery and chemotherapy for disease confined to the lung. The academic-led trial will impact lung cancer patients following standard treatment. Lung cancer is the second most common cancer in North America and is the leading cancer killer in both men and women. NSCLC accounts for 80-85 per cent of all lung cancer cases.
Canadian Cancer Trials Group BR.31 will enroll 1100 patients from Canada and around the world. The Canadian Cancer Trials Group, a national research program of the Canadian Cancer Society whose Central Operations and Statistics Office is located at Queen's University in Kingston, Canada, will lead the trial in Canada. The Canadian Cancer Trials Group is also extremely pleased that the trial includes participation of a number of international collaborators including the Intergroupe Francophone de Cancerologie Thoracique (France), the National Cancer Institute, Naples (Italy), the Australasian Lung Cancer Trials Group & National Health and Medical Research Council Clinical Trials Centre (Australia), the Spanish Lung Cancer Group, the Dutch Society for Pulmonology and Tuberculosis (NVALT), the Central and East European Oncology Group, the Korean Cancer Study Group, and the National Cancer Centre Singapore.
Activation of the trial was officially announced at a press conference held at Queen's University in Kingston, Canada this past Monday, November 10, 2014. Speakers at the event included Dr. Daniel Woolf, Principal of Queen's University, Dr. Steven Liss, VP Research at Queen's, Dr. Richard Reznick, Dean of the Faculty of Health Sciences at Queen's, Dr. Glen Goss, Co-Chair of the Canadian Cancer Trials Group's Lung Site Committee and international chair of BR.31, Dr. Janet Dancey, Director of the Canadian Cancer Trials Group, Dr. Chris O'Callaghan, Canadian Cancer Trials Group Senior Investigator, Elaine Campbell, President of AstraZeneca Canada, and Carol Gething, lung cancer survivor.
Click here for pictures taken during the event:
News of the activation of Canadian Cancer Trials Group BR.31 was covered by several media outlets. For your interest, we have collected links to the stories and you can view/listen to them here:
CBC Ottawa Morning - Audio only
The Kingston Whig-Standard - http://www.thewhig.com/2014/11/11/queens-at-forefront-of-new-cancer-drug-trial
CKWS TV, Kingston, Ontario - http://www.ckwstv.com/2014/11/10/new-clinical-trial-helps-find-a-drug-to-cure-cancer/
Station 14, Kingston, Ontario - http://www.station14.ca/video.html?id=1258
Canadian Cancer Society - http://www.cancer.ca/en/about-us/for-media/media-releases/national/2014/ncic-lung-cancer/?region=on
Queen's University Official Media Release - http://www.queensu.ca/gazette/media/queens-university-ncic-ctg-announce-cutting-edge-lung-cancer-trial
Queen's University "Dean on Campus" - http://meds.queensu.ca/blog/?p=2826
More information about the Canadian Cancer Trials Group and the international BR.31 collaborators follows:
About the Canadian Cancer Trials Group (CTG)
The Canadian Cancer Trials Group is the only Canadian cooperative cancer trials group conducting the entire range of cancer trials from early phase studies to large international randomized controlled trials across all cancer types. Its primary mission is to assess the effectiveness of interventions to prevent the development of cancer or improve the care of those patients who do develop cancer. Canadian Cancer Trials Group trials have led to improved outcomes for cancer patients. It is a national research program of the Canadian Cancer Society. The Canadian Cancer Trials Group's Central Operations and Statistics Office is located at Queen's University in Kingston, Ontario, Canada. You can visit their website at http://www.ctg.queensu.ca.
About the French Cooperative Thoracic Intergroup
The French Cooperative Thoracic Intergroup (IFCT) is a multicentre (> 300 hospitals in France, general and university hospital, as well as cancer centers) cancer research cooperative group certified by French NCI (INCa) and French Cancer League. The IFCT has had previous experience in early-stage lung cancer trials with more than 1000 patients enrolled each year in its thoracic cancer clinical trials or translational research programs. You can visit their website at http://www.ifct.fr.
About the National Cancer Institute of Naples
The National Cancer Institute of Naples (NCI-N) has produced significant contributions over a 20-year history of clinical trials. The NCI-N will coordinate Italian participation in BR.31. You can visit the Instituto Nazionale dei Timori at http://www.istitutotumori.mi.it/.
About the Australasian Lung Cancer Trials Group and the National Health and Medical Research Council Clinical Trials Centre
The Australasian Lung Cancer Trials Group (ALTG) is a multidisciplinary cancer cooperative trials group dedicated to reducing the incidence, morbidity and mortality of lung and other thoracic cancers through cancer clinical trials. The National Health and Medical Research Council Clinical Trials Centre (NHMRC CTC) at the University of Sydney runs investigator-initiated, multicentre clinical trials in cancer and other diseases. It is the coordinating and statistical centre for 5 cancer cooperative trials groups based in Australia and New Zealand. You can visit their websites at http://www.altg.com.au/ and http://ctc.usyd.edu.au/.
About the Spanish Lung Cancer Group
The Spanish Lung Cancer Group (SPLG) is a multicenter collaborative group with > 100 hospitals in Spain and has extensive experience conducting trials in early stage lung cancer. You can visit their website at http://www.gecp.org.
About the Dutch Society for Pulmonology and Tuberculosis
The Dutch Society for Pulmonology and Tuberculosis (NVALT) will conduct BR.31 in The Netherlands. You can visit their website at http://www.nvalt.nl.
About the Central and East European Oncology Group
The aim of the Central and East European Oncology Group (CEEOG) is to conduct phase II and III clinical trials of novel anticancer agents and regimens in common malignancies, including breast cancer, ovarian cancer, lung cancer and head and neck cancer. It includes 35 academic and community hospitals from Poland, Romania, Slovakia, Bulgaria, Slovenia, Croatia, Bosnia and Hercegovina, Yugoslavia, Hungary, Czech Republic and Russia. You can visit their website at http://www.ceeog.org/.
About the Korean Cancer Study Group
The Korean Cancer Study Group (KCSG) was established in 1988 as a sub-organization of the Korean Cancer Association. The KCSG constantly attempts to advance oncology through collaborative cancer studies, presenting the rational policy to improve chemotherapies and the clinical trial practice, with the ultimate goal of fostering and enhancing public health. You can visit their website at http://www.kcsg.org/eng/about/sub01.html.
About the National Cancer Centre Singapore
The National Cancer Centre Singapore (NCCS) became a national cancer centre in 1999 and tends to almost 75% of the cancer patients in Singapore and about 10% of foreign patients in the region. The NCCS relentlessly pursues a robust research-based approach to confront the disease. You can visit their website at http://www.nccs.com.sg/Pages/Home.aspx.
More information about Queen's University, the Canadian Cancer Society and Astra Zeneca follows:
About Queen's University
For over 170 years, Queen's University has been a leader in higher education, as well as in shaping Canada's future. Queen's ranks amongst the top 10 research-intensive universities in Canada, and does so as a mid-sized residential university, with a strong sense of community and purpose. At the core of its success is the Queen's commitment to research excellence, and an inextricable link that binds teaching and research with the common fundamental thread of learning.
About the Canadian Cancer Society
The Canadian Cancer Society is a national, community-based organization of volunteers whose mission is to eradicate cancer and enhance the quality of life of people living with cancer. Thanks to its donors and volunteers, the Society has the most impact, against the most cancers, in the most communities in Canada. Building on its progress, CCS is working with Canadians to change cancer forever. You can visit CCS's website at http://cancer.ca.
AstraZeneca is a global, innovation-driven biopharmaceutical business with a primary focus on the discovery, development and commercialization of prescription medicines for gastrointestinal, cardiovascular, neuroscience, respiratory and inflammation, oncology and infectious disease. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. AstraZeneca's Canadian headquarters are located in Mississauga, Ontario.
For Information About Participating in Canadian Cancer Trials Group BR.31
For more information about Canadian Cancer Trials Group BR.31, please contact Dr. Chris O'Callaghan, Canadian Cancer Trials Group Senior Investigator, at email@example.com or Anne-Marie Bradley, Canadian Cancer Trials Group Study Coordinator, at firstname.lastname@example.org.